Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care
详细信息 查看全文
- 作者：Didier Meulendijksa ; b ; J.G. Coen van Hasseltc ; Alwin D.R. Huitemad ; Harm van Tinterene ; Maarten J. Deenena ; b ; Jos H. Beijnend ; f ; Annemieke Catsg ; Jan H.M. Schellensa ; b ; f ; j.schellens@nki.nl" class="auth_mail" title="E-mail the corresponding author
- 关键词：Fluoropyrimidine-associated toxicity ; Capecitabine ; Safety ; adverse events ; Toxicity
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：54
- 期：Complete
- 页码：120-130
- 全文大小：1797 K
文摘
- •
Fluoropyrimidines are used by approximately 2 million patients worldwide each year.
- •
We examined the factors related to early severe fluoropyrimidine-related toxicity.
- •
In total, 1463 patients treated in routine clinical care were analysed.
- •
Renal function, BSA, DPD deficiency, and age were related to early severe toxicity.
- •
These factors are associated with clinically relevant differences in risk of early severe toxicity.